Skip to main content

Cardiac Failure

0
Pipeline Programs
7
Companies
7
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

iNova Pharmaceuticals
iNova PharmaceuticalsAustralia - Chatswood
2 programs
OPtimal Adult Heart Transplant Immunosuppression With MicroRNA LevelsN/A1 trial
Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAsN/A1 trial
Active Trials
NCT06939751Recruiting250Est. Jan 2032
NCT06532890Recruiting150Est. Oct 2029
Baxter
BaxterCosta Rica - Cartago
1 program
Cova PatchN/A
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
Cova PatchN/A1 trial
Active Trials
NCT04255108Completed50Est. Apr 2020
Baxter International
1 program
Cova PatchN/A
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
Heart Failure Disease Management ProgramN/A1 trial
Active Trials
NCT01822912Completed713Est. Mar 2019
Bristol Myers Squibb
1 program
BMS-986224PHASE_12 trials
Active Trials
NCT03634969Completed50Est. Apr 2019
NCT03563950Completed42Est. Jul 2018
Takeda
TakedaTOKYO, Japan
1 program
Ferric carboxymaltosePHASE_41 trial
Active Trials
NCT03871699Unknown20Est. Feb 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
TakedaFerric carboxymaltose
Bristol Myers SquibbBMS-986224
Bristol Myers SquibbBMS-986224
iNova PharmaceuticalsOPtimal Adult Heart Transplant Immunosuppression With MicroRNA Levels
iNova PharmaceuticalsOptimal Pediatric Heart Transplant Immunosuppression With MicroRNAs
Angeles TherapeuticsCova Patch
Colorado TherapeuticsHeart Failure Disease Management Program

Clinical Trials (7)

Total enrollment: 1,275 patients across 7 trials

NCT03871699TakedaFerric carboxymaltose

Ferric Carboximaltose on Intra-myocardial Iron Load in Patients With Heart Failure

Start: Aug 2019Est. completion: Feb 202120 patients
Phase 4Unknown
NCT03634969Bristol Myers SquibbBMS-986224

An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants

Start: Aug 2018Est. completion: Apr 201950 patients
Phase 1Completed
NCT03563950Bristol Myers SquibbBMS-986224

An Investigational Study to Evaluate the Effect of Rifampin on the Singe Dose of Experimental Medication BMS-986224 in Healthy Participants

Start: Jun 2018Est. completion: Jul 201842 patients
Phase 1Completed
NCT06939751iNova PharmaceuticalsOPtimal Adult Heart Transplant Immunosuppression With MicroRNA Levels

OPtimal Adult Heart Transplant Immunosuppression With MicroRNA Levels

Start: Oct 2025Est. completion: Jan 2032250 patients
N/ARecruiting
NCT06532890iNova PharmaceuticalsOptimal Pediatric Heart Transplant Immunosuppression With MicroRNAs

Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs

Start: Feb 2025Est. completion: Oct 2029150 patients
N/ARecruiting
NCT04255108Angeles TherapeuticsCova Patch

Validation of a Sensor for Non-invasive Measurement of Stroke Volume and Cardiac Output

Start: Feb 2020Est. completion: Apr 202050 patients
N/ACompleted
NCT01822912Colorado TherapeuticsHeart Failure Disease Management Program

Heart Failure Management Program Versus Usual Care

Start: Jan 2013Est. completion: Mar 2019713 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 1,275 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.